Pharma Pulse 1/20/25: Rare Drug Development and Chrysalis Genetics, Evaluating the Cost-Effectiveness of NSCLC Treatment & more

Casey McPherson Shares His Journey With Rare Drug Development and Chrysalis Genetics

Casey McPherson, Founder and CEO of Chrysalis Genetics, has an interesting background for someone developing genetic technologies to help treat rare diseases. As a musician based in Austin, Texas, McPherson was inspired to enter the world of drug development and biotechnology after his daughter was diagnosed with a rare genetic condition. In this Pharmaceutical Executive interview, McPherson talks about his journey toward developing a therapeutic for his daughter, as well as changing the overall landscape of therapeutic research for children with rare or ultra-rare genetic diseases.

Evaluating the Cost-Effectiveness of NSCLC Treatments: New Insights From a Recent Review

But many existing models fall short of adhering to established best practices for economic evaluation, the review authors found. Another challenge: Existing models may not be well-suited for evaluating personalized treatments.

Biden Issues 11th-Hour Cyber Executive Order

Brandishing $102 billion in I.T. purchasing power, the U.S. will require tech firms that want government contracts to meet higher security standards, the White House says.

Second Round of Medicare Drug Price Controls Perpetuates Flawed, Harmful Policy

The Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 new drugs to be subject to price controls under the Inflation Reduction Act (IRA) represents the continuation of a flawed federal policy that has failed to achieve its stated goals and is causing significant health and economic harm.

Donald Prentiss on LinkedIn

I want to thank Nicholas Saraceno and Pharmaceutical Commerce Magazine for the opportunity to discuss the role of compounding pharmacies and their contributions during critical drug shortages. Our conversation highlighted two key points:

1. Bridging Gaps During Shortages – Compounding pharmacies have stepped up to meet patient needs when supply chain disruptions occur, as seen with tirzepatide and similar cases. This highlights their role as a vital part of the healthcare ecosystem.

2. Collaboration Over Competition – Commercial and compounded medications are not competitors but rather complementary solutions addressing different patient needs. By fostering collaboration between compounders, manufacturers, and regulators, we can better serve patients and ensure access to essential therapies.

Thank you again to Nicholas Saraceno and the team at Pharmaceutical Commerce Magazine for bringing attention to these important topics.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs